GLP-1 drugs like semaglutide and liraglutide are revolutionizing diabetes and obesity care by enhancing glucose control and driving weight loss. Their complex manufacturing spanning peptide synthesis, formulation, sterile injectables, and cold-chain logistics poses challenges but also opportunities. With global demand soaring and annual sales projected to exceed $100 billion by 2030, supply chain bottlenecks and device shortages remain critical barriers. As patents for blockb